Oui, un suivi régulier est essentiel pour surveiller les niveaux de prolactine et la taille de la tumeur.
Suivi médicalProlactinomeProlactine
Complications
5
#1
Quelles complications peuvent survenir avec un prolactinome ?
Les complications incluent des troubles visuels, des maux de tête persistants et des déséquilibres hormonaux.
ComplicationsTroubles visuelsProlactinome
#2
Le prolactinome peut-il affecter la fertilité ?
Oui, l'excès de prolactine peut entraîner des problèmes de fertilité chez les femmes et les hommes.
FertilitéProlactinomeDéséquilibres hormonaux
#3
Y a-t-il un risque de récidive après traitement ?
Oui, il existe un risque de récidive, surtout si le traitement médicamenteux est interrompu.
RécidiveProlactinomeTraitement
#4
Les troubles de la vision sont-ils réversibles ?
Cela dépend de la gravité; certains troubles peuvent s'améliorer après traitement, d'autres non.
Troubles de la visionProlactinomeTraitement
#5
Le prolactinome peut-il causer des problèmes psychologiques ?
Oui, les déséquilibres hormonaux peuvent contribuer à des problèmes d'anxiété ou de dépression.
AnxiétéDépressionProlactinome
Facteurs de risque
5
#1
Quels sont les facteurs de risque du prolactinome ?
Les facteurs incluent des antécédents familiaux, des troubles hormonaux et des maladies hypophysaires.
Facteurs de risqueProlactinomeAntécédents familiaux
#2
Le stress peut-il aggraver un prolactinome ?
Oui, le stress peut influencer les niveaux de prolactine et aggraver les symptômes.
StressProlactinomeHormones
#3
Les femmes sont-elles plus à risque ?
Oui, les prolactinomes sont plus fréquents chez les femmes, surtout entre 20 et 50 ans.
ProlactinomeFemmesHormones
#4
Y a-t-il un lien avec d'autres maladies endocriniennes ?
Oui, des maladies comme l'hypothyroïdie peuvent être associées à des niveaux élevés de prolactine.
Maladies endocriniennesHypothyroïdieProlactinome
#5
L'utilisation de médicaments peut-elle être un facteur ?
Oui, certains médicaments, comme les antipsychotiques, peuvent augmenter les niveaux de prolactine.
MédicamentsProlactinomeAntipsychotiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Prolactinome : Questions médicales les plus fréquentes",
"headline": "Prolactinome : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Prolactinome : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-03",
"dateModified": "2026-04-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Prolactinome"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs de l'hypophyse",
"url": "https://questionsmedicales.fr/mesh/D010911",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de l'hypophyse",
"code": {
"@type": "MedicalCode",
"code": "D010911",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C19.700.734"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Prolactinome",
"alternateName": "Prolactinoma",
"code": {
"@type": "MedicalCode",
"code": "D015175",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ilan Shimon",
"url": "https://questionsmedicales.fr/author/Ilan%20Shimon",
"affiliation": {
"@type": "Organization",
"name": "Institute of Endocrinology, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel, ilanshi@clalit.org.il."
}
},
{
"@type": "Person",
"name": "Thomas Cuny",
"url": "https://questionsmedicales.fr/author/Thomas%20Cuny",
"affiliation": {
"@type": "Organization",
"name": "Service d'Endocrinologie, Hôpital de la Conception, Inserm U1251, Marseille Medical Genetics, APHM, Aix-Marseille University, Marseille, France."
}
},
{
"@type": "Person",
"name": "Sunita M C De Sousa",
"url": "https://questionsmedicales.fr/author/Sunita%20M%20C%20De%20Sousa",
"affiliation": {
"@type": "Organization",
"name": "Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia. Sunita.DeSousa@sa.gov.au."
}
},
{
"@type": "Person",
"name": "Roberto Salvatori",
"url": "https://questionsmedicales.fr/author/Roberto%20Salvatori",
"affiliation": {
"@type": "Organization",
"name": "Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, and Pituitary Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. salvator@jhmi.edu."
}
},
{
"@type": "Person",
"name": "Jian Song",
"url": "https://questionsmedicales.fr/author/Jian%20Song",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurosurgery, The General Hospital of Chinese People's Liberation Army Central Theater Command, Wuhan, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Prolactinomas: Preconception and During Pregnancy.",
"datePublished": "2024-06-18",
"url": "https://questionsmedicales.fr/article/39084816",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ecl.2024.05.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "The treatment of aggressive prolactinomas with everolimus.",
"datePublished": "2023-07-10",
"url": "https://questionsmedicales.fr/article/37428396",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11102-023-01340-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Giant prolactinomas, a detailed analysis of 196 adult cases.",
"datePublished": "2023-08-07",
"url": "https://questionsmedicales.fr/article/37544978",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11102-023-01337-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "The clinical and therapeutic profiles of prolactinomas associated with germline pathogenic variants in the",
"datePublished": "2023-08-29",
"url": "https://questionsmedicales.fr/article/37711900",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2023.1242588"
}
},
{
"@type": "ScholarlyArticle",
"name": "Syndrome of inappropriate antidiuretic hormone with recurrent giant cabergoline-resistant prolactinoma.",
"datePublished": "2023-09-28",
"url": "https://questionsmedicales.fr/article/37770242",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/bcr-2023-255422"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies endocriniennes",
"item": "https://questionsmedicales.fr/mesh/D004700"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies de l'hypophyse",
"item": "https://questionsmedicales.fr/mesh/D010900"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs de l'hypophyse",
"item": "https://questionsmedicales.fr/mesh/D010911"
},
{
"@type": "ListItem",
"position": 5,
"name": "Prolactinome",
"item": "https://questionsmedicales.fr/mesh/D015175"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Prolactinome - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Prolactinome",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Prolactinome",
"description": "Comment diagnostique-t-on un prolactinome ?\nQuels tests sanguins sont nécessaires ?\nQuels signes d'imagerie indiquent un prolactinome ?\nLe prolactinome peut-il être confondu avec d'autres tumeurs ?\nQuels symptômes peuvent alerter au prolactinome ?",
"url": "https://questionsmedicales.fr/mesh/D015175#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Prolactinome",
"description": "Quels sont les symptômes courants d'un prolactinome ?\nLe prolactinome cause-t-il des maux de tête ?\nLes hommes peuvent-ils avoir des symptômes ?\nComment la galactorrhée se manifeste-t-elle ?\nY a-t-il des symptômes psychologiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D015175#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Prolactinome",
"description": "Quels traitements sont disponibles pour le prolactinome ?\nLes médicaments sont-ils efficaces ?\nQuand la chirurgie est-elle nécessaire ?\nY a-t-il des effets secondaires aux traitements ?\nLe suivi est-il important après le traitement ?",
"url": "https://questionsmedicales.fr/mesh/D015175#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Prolactinome",
"description": "Quelles complications peuvent survenir avec un prolactinome ?\nLe prolactinome peut-il affecter la fertilité ?\nY a-t-il un risque de récidive après traitement ?\nLes troubles de la vision sont-ils réversibles ?\nLe prolactinome peut-il causer des problèmes psychologiques ?",
"url": "https://questionsmedicales.fr/mesh/D015175#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Prolactinome",
"description": "Quels sont les facteurs de risque du prolactinome ?\nLe stress peut-il aggraver un prolactinome ?\nLes femmes sont-elles plus à risque ?\nY a-t-il un lien avec d'autres maladies endocriniennes ?\nL'utilisation de médicaments peut-elle être un facteur ?",
"url": "https://questionsmedicales.fr/mesh/D015175#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un prolactinome ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins pour mesurer la prolactine et des IRM de l'hypophyse."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont nécessaires ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages de prolactine, TSH et hormones hypophysaires sont effectués."
}
},
{
"@type": "Question",
"name": "Quels signes d'imagerie indiquent un prolactinome ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une masse hypophysaire sur l'IRM avec élévation des niveaux de prolactine."
}
},
{
"@type": "Question",
"name": "Le prolactinome peut-il être confondu avec d'autres tumeurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il peut être confondu avec d'autres adénomes hypophysaires ou tumeurs cérébrales."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent alerter au prolactinome ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des irrégularités menstruelles, galactorrhée ou troubles de la vision peuvent alerter."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants d'un prolactinome ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent galactorrhée, aménorrhée, et troubles de la libido."
}
},
{
"@type": "Question",
"name": "Le prolactinome cause-t-il des maux de tête ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maux de tête peuvent survenir en raison de la pression exercée par la tumeur."
}
},
{
"@type": "Question",
"name": "Les hommes peuvent-ils avoir des symptômes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les hommes peuvent éprouver une diminution de la libido et des troubles érectiles."
}
},
{
"@type": "Question",
"name": "Comment la galactorrhée se manifeste-t-elle ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "La galactorrhée se manifeste par l'écoulement de lait des seins en dehors de l'allaitement."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes psychologiques associés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'anxiété ou la dépression peuvent être liés aux déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour le prolactinome ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des médicaments comme les agonistes de la dopamine et la chirurgie si nécessaire."
}
},
{
"@type": "Question",
"name": "Les médicaments sont-ils efficaces ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les agonistes de la dopamine réduisent la taille de la tumeur et normalisent la prolactine."
}
},
{
"@type": "Question",
"name": "Quand la chirurgie est-elle nécessaire ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est envisagée si les médicaments échouent ou en cas de complications visuelles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des nausées, des vertiges ou des troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Le suivi est-il important après le traitement ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour surveiller les niveaux de prolactine et la taille de la tumeur."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec un prolactinome ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles visuels, des maux de tête persistants et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Le prolactinome peut-il affecter la fertilité ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'excès de prolactine peut entraîner des problèmes de fertilité chez les femmes et les hommes."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque de récidive après traitement ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il existe un risque de récidive, surtout si le traitement médicamenteux est interrompu."
}
},
{
"@type": "Question",
"name": "Les troubles de la vision sont-ils réversibles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la gravité; certains troubles peuvent s'améliorer après traitement, d'autres non."
}
},
{
"@type": "Question",
"name": "Le prolactinome peut-il causer des problèmes psychologiques ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les déséquilibres hormonaux peuvent contribuer à des problèmes d'anxiété ou de dépression."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque du prolactinome ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des troubles hormonaux et des maladies hypophysaires."
}
},
{
"@type": "Question",
"name": "Le stress peut-il aggraver un prolactinome ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut influencer les niveaux de prolactine et aggraver les symptômes."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les prolactinomes sont plus fréquents chez les femmes, surtout entre 20 et 50 ans."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec d'autres maladies endocriniennes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme l'hypothyroïdie peuvent être associées à des niveaux élevés de prolactine."
}
},
{
"@type": "Question",
"name": "L'utilisation de médicaments peut-elle être un facteur ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains médicaments, comme les antipsychotiques, peuvent augmenter les niveaux de prolactine."
}
}
]
}
]
}
Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia. Sunita.DeSousa@sa.gov.au.
Department of Genetics and Molecular Pathology, Centre for Cancer Biology, an SA Pathology and University of South Australia Alliance, Adelaide, Australia. Sunita.DeSousa@sa.gov.au.
School of Medicine, University of Adelaide, Adelaide, Australia. Sunita.DeSousa@sa.gov.au.
Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, and Pituitary Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. salvator@jhmi.edu.
Endocrine Unit and Neuroendocrinology Research Center, Medical School and Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil; Neuroendocrine Unit - Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil; Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do Cérebro Paulo Niemeyer, Secretaria Estadual de Saúde, Rio de Janeiro, Brazil. Electronic address: mgadelha@hucff.ufrj.br.
College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; Division of Neurosurgery, Department of Surgery, King Abdulaziz Medical City, Ministry of National Guard - Health Affairs, Riyadh, Saudi Arabia. Electronic address: AlkhaibaryA@hotmail.com.
INSERM U1052, CNRS UMR5286, Cancer Research Center of Lyon, 69008, Lyon, Auvergne-Rhône-Alpes, France.
Lyon 1 University, 69100, Villeurbanne, Auvergne-Rhône-Alpes, France.
Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, "Groupement Hospitalier Est" Hospices Civils de Lyon, Auvergne-Rhône-Alpes, 69677, Bron, France.
Service de neurochirurgie, hôpital de la Timone, Timone, France; Aix Marseille université, centre de références maladies rares HYPO, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
Service d'endocrinologie, hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France; Aix Marseille université, centre de références maladies rares HYPO, Assistance Publique-Hôpitaux de Marseille, Marseille, France.
Institute of Endocrinology, Metabolism, Diabetes and Hypertension, Tel Aviv-Sourasky Medical Center, 6 Weizmann Street, 64239, Tel Aviv, Israel. yonagr@tlvmc.gov.il.
Tel Aviv University, Tel Aviv, Israel. yonagr@tlvmc.gov.il.
Division of Endocrinology, Diabetes, & Metabolism, Department of Medicine, and Pituitary Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Division of Endocrinology and Nutrition, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, dominique.maiter@uclouvain.be.
Prolactinomas are a common cause of infertility in women. Medical treatment with dopamine agonists (DAs) has an excellent efficacy at restoring fertility and a reassuring safety profile in early pregn...
Aggressive prolactinomas are life-limiting tumors without a standard of care treatment option after the oral alkylator, temozolomide, fails to provide tumor control....
We reviewed an institutional database of pituitary tumors for patients with aggressive prolactinomas who progressed following treatment with a dopamine receptor agonist, radiotherapy and temozolomide....
Three of four patients who were treated with everolimus had a biochemical response to therapy and all patients derived a clinically meaningful benefit based upon suppression of tumor growth. While the...
Everolimus is an active agent in the treatment of prolactinomas that warrants further investigation....
Giant prolactinomas are a rare entity, representing approximately 5% of all prolactinomas. A systematic review of 196 adult cases was performed. A comparison of the clinical, biochemical and radiologi...
A structured search was conducted using the term 'giant prolactinoma'. Following inclusion criteria were used: diameter ≥ 40 mm, prolactin levels > 1000 ng/ml and no concomitant GH/ ACTH secretion....
196 cases were included [age: 38 (28-50) years, F/M ratio: 1/3.6]. Median tumor diameter was 53 (43-69) mm. Pituitary deficiency was present in 91% of cases, with hypogonadotropic hypogonadism being t...
Giant prolactinomas are rare and have a male predominance. Visual impairment is the most frequent presenting symptom in men and amenorrhea in women. The gender-related difference in tumor size and lev...
Prolactinomas are the most frequent type of pituitary adenoma encountered in clinical practice. Dopamine agonists (DA) like cabergoline typically provide sign/ symptom control, normalize prolactin lev...
We compared the clinical, radiological, and therapeutic characteristics of AIPvar-related prolactinomas (n=13) with unselected hospital-treated prolactinomas ("unselected", n=41) and genetically-negat...
AIPvar-related prolactinomas occurred at a significantly younger age than the unselected or DA-resistant prolactinomas (p<0.01). Males were more common in the AIPvar (75.0%) and DA- resistant (49.7%) ...
AIPvar confer an aggressive phenotype in prolactinomas, with invasive tumors occurring at a younger age. These characteristics can help differentiate rare AIPvar related prolactinomas from DA-resistan...
A macro pituitary tumour or giant pituitary tumour is regarded as a rare causal factor in syndrome of inappropriate antidiuretic hormone (SIADH) cases. Previous reports have presented findings showing...
Giant prolactinomas (GP) are rare tumors accounting for 4.3% of prolactinomas, with paucity of literature from India. We aim to describe clinical, biochemical, radiological, and treatment outcomes in ...
A single-center retrospective analysis of GPs (n=84), age-based (adults: 66 versus pediatric: 18) and gender-based (males: 64 versus females: 20) comparison was done....
The mean age at presentation was 34.1±13years, and 64 (76.2%) were males. Males were younger at presentation (32.1±12.2 versus 40.1±13.8years, P: 0.01). The majority presented with mass-effect-related...
GP has male predominance, DA as first-line therapy normalized prolactin in four-fifths of patients with better preservation of HPT and HPA axes in patients with DA monotherapy....
Prolactinomas-pituitary tumors that overproduce prolactin-can cause various troublesome symptoms. Dopamine agonists (DAs) reduce prolactin production in the prolactin pathway, making them the first-li...
This review examined PubMed citations from 1960 to 2023 published in English and involving human subjects. Case reports, case series, and cohort studies involving patients with concomitant prolactinom...
Thematic analysis included 23 reports involving 42 participants; 27 of the 42 patients experienced a significant reduction in prolactin levels and psychiatric symptoms (64%). Treatment of those 42 pat...
Clinicians may find it beneficial to prioritize specific antipsychotics (aripiprazole, olanzapine, ziprasidone, or clozapine) over others (risperidone, thioridazine, thiothixene, and remoxipride). Dis...
Only a limited number of studies have focused on the results of the Endoscopic Endonasal Approach (EEA) for treatment of prolactinomas. We sought to assess the effectiveness of EEA for prolactinoma su...
An increase of IGF-1 has been reported during therapy with dopamine agonists (DA) for prolactinomas; in such cases a correct diagnosis is pivotal to avoid an unnecessary reduction or withdrawal of DA,...
We retrospectively enrolled 35 patients (15 F/20 M; age m ± SD, years: 43.4 ± 13.7) with prolactinoma (21 microadenomas and 14 macroadenomas) who were followed-up at the Endocrinology Unit, in Siena, ...
IGF-1 increased in the whole cohort, but remaining within normal range, except two patients, in whom acromegaly was ruled out with oral glucose tolerance test. After dividing patients by weight, this ...
Since DA and normalization of prolactin are known to improve insulin sensitivity, we speculated they have favored the increase of IGF-1 in OV/OB. Our results should be confirmed and the hypothesis pro...
To describe care trajectories in patients with prolactinoma, aiming to clarify the rationale for surgery....
Retrospective observational cohort study of consecutive patients with prolactinoma undergoing surgery from 2017 to 2019 at the referral center (RC), prior to surgery being considered a viable treatmen...
40 patients were included (31 females (77.5%), median age 26.5 (14-63) years. Indications for surgery were dopamine agonist (DA) intolerance (n = 31, 77.5%), resistance (n = 6, 15.0%), and patient/phy...
Care trajectories were highly individualized based on patient and tumor characteristics, as well as the multidisciplinary team's assessment (need for alternative treatment, surgical chances and risks)...